Academic literature on the topic 'Neuroprotective agents'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Neuroprotective agents.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Neuroprotective agents"
Sunjoyo, Ageng, and Andy Nugroho. "Neuroprotective Agents: A Simple Overview." Open Access Macedonian Journal of Medical Sciences 10, F (September 2, 2022): 578–82. http://dx.doi.org/10.3889/oamjms.2022.10329.
Full textRichardson, J. Steven. "Neuroprotective Agents." Physical Medicine and Rehabilitation Clinics of North America 10, no. 2 (May 1999): 447–61. http://dx.doi.org/10.1016/s1047-9651(18)30205-5.
Full textHilton, Genell. "Experimental Neuroprotective Agents." Dimensions Of Critical Care Nursing 14, no. 4 (July 1995): 181–88. http://dx.doi.org/10.1097/00003465-199507000-00004.
Full textSánchez, A. J., and A. García-Merino. "Neuroprotective agents: Cannabinoids." Clinical Immunology 142, no. 1 (January 2012): 57–67. http://dx.doi.org/10.1016/j.clim.2011.02.010.
Full textYanık, Tuğra, and Burcu Yanık. "Current neuroprotective agents in stroke." Turkish Journal of Physical Medicine and Rehabilitation 70, no. 2 (May 16, 2024): 157–63. http://dx.doi.org/10.5606/tftrd.2024.15287.
Full textDouna, H., B. M. Bavelaar, H. Pellikaan, B. Olivier, and T. Pieters. "Neuroprotection in Parkinson's Disease: A Systematic Review of the Preclinical Data." Open Pharmacology Journal 6, no. 1 (May 9, 2012): 12–26. http://dx.doi.org/10.2174/1874143601206010012.
Full textDugan, L. L., D. M. Turetsky, C. Du, D. Lobner, M. Wheeler, C. R. Almli, C. K. F. Shen, T. Y. Luh, D. W. Choi, and T. S. Lin. "Carboxyfullerenes as neuroprotective agents." Proceedings of the National Academy of Sciences 94, no. 17 (August 19, 1997): 9434–39. http://dx.doi.org/10.1073/pnas.94.17.9434.
Full textCores, Ángel, Noelia Carmona-Zafra, José Clerigué, Mercedes Villacampa, and J. Carlos Menéndez. "Quinones as Neuroprotective Agents." Antioxidants 12, no. 7 (July 20, 2023): 1464. http://dx.doi.org/10.3390/antiox12071464.
Full textAli Esmail Al-Snafi. "Medicinal Plants with neuroprotective effects." GSC Biological and Pharmaceutical Sciences 17, no. 1 (October 30, 2021): 213–31. http://dx.doi.org/10.30574/gscbps.2021.17.1.0319.
Full textO'Mara, Keliana, and Christopher McPherson. "Neuroprotective Agents for Neonates with Hypoxic-Ischemic Encephalopathy." Neonatal Network 40, no. 6 (November 1, 2021): 406–13. http://dx.doi.org/10.1891/11-t-755.
Full textDissertations / Theses on the topic "Neuroprotective agents"
Nilsson, Olov. "Cannabinoids as neuroprotective agents : a mechanistic study." Doctoral thesis, Umeå : Umeå universitet, 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-873.
Full textBadenhorst, Hester Elizabeth. "Antihistamines as neuroprotective agents / Hester Elizabeth Badenhorst." Thesis, North-West University, 2004. http://hdl.handle.net/10394/95.
Full textThesis (M.Sc. (Pharmaceutical Chemistry))--North-West University, Potchefstroom Campus, 2005.
Egunlusi, Ayodeji Olatunde. "Novel norbornane derivatives as potential neuroprotective agents." University of Western Cape, 2020. http://hdl.handle.net/11394/7339.
Full textNeurodegenerative disorders are characterised by progressive loss of the brain’s physiological functions as a result of gradual degeneration of neurons in the central nervous system. Even though they are classified as diseases of the elderly, occurrence earlier in life is possible, but that would suggest the influence of genetic and/or environmental factors. Due to the continuous rise in modernisation and industrialisation over the years, there has been an increase in incidence and prevalence of neurodegenerative disorders. With the advances in technology and life expectancy, the rates of the common forms (Alzheimer’s disease and Parkinson’s disease), are expected to increase exponentially by 2050. Unfortunately, there is still no clinically approved treatment or therapy to slow down or halt the degenerative process as most registered drugs only offer symptomatic relief. Confounding this issue is the lack of definite mechanism of neurodegeneration, which is still poorly defined and not completely understood. Nonetheless, the pathology of most neurodegenerative disorders is believed to be a combination of interrelated processes that eventually leads to neuronal cell death. Among the postulated processes, the impact of excitotoxicity mediated by NMDA receptor over-activation is prominent and it is implicated in virtually all neurodegenerative disorders. With this basic insight, it is believed that molecules capable of inhibiting NMDA receptors and associated calcium channels, without affecting the normal physiological functions of the brain, could potentially serve as good neuroprotective drugs. Competitive and uncompetitive blockers (MK-801 and ketamine) have been explored, but none were clinically accepted due to undesirable side effects such as hallucinations, sedation and depression. However, NGP1-01, a polycyclic cage molecule, has been shown to be neuroprotective through modulation of NMDA receptors and voltage gated calcium channels and attenuation of MPP+ -induced toxicity. A similar approach could be useful in the design and development of new neuroprotective drugs. The aim of this study was to synthesise a series of open and rearranged cage-like molecules and explore their neuroprotective potential in neuroblastoma SH-SY5Y cells. The proposed structures, with norbornane scaffolds that contained different moieties, were designed to structurally resemble NGP1-01 and MK-801. Once synthesised, the compounds were purified and characterised, and were evaluated for their biological activities. Compounds were first screened for cytotoxicity at different concentrations. Thereafter, they were evaluated for neuroprotective effects against MPP+ -induced excitotoxicity and for calcium flux modulatory effects on NMDA receptor and voltage gated calcium channels. The norbornane derivatives were synthesised and characterised, and all final products were afforded in sufficient yields. All compounds with the exception of two compounds displayed good cytotoxic profiles towards the SH-SY5Y neuroblastoma cells at 10 µM, 50 µM and 100 µM concentrations as they demonstrated percentage cell viabilities close to 100% (control treated cells). Only two compounds showed percentage cell viability of 51% and 59% at 100 µM. Utilising the same cell line, all compounds, tested at 10 µM, attenuated MPP+ -induced toxicity after 24 hours of exposure to a neurotoxin. This was evident in the 23% to 53% enhancement (significant with p < 0.05) in cell viability when compared to the MPP+ only treated cells. In comparison to known NMDA receptor and/or voltage gated calcium channel blockers (MK-801, NGP1-01 or nimodipine), the synthesised compounds demonstrated mono or dual inhibition of calcium channels as they effectively attenuated calcium influx by blocking NMDA receptors and/or voltage gated calcium channels expressed in neuroblastoma SHSY5Y cells. This group of compounds were found to be more potent NMDA receptor inhibitors, probably due to similarities with MK-801 and memantine, than voltage gated calcium channel inhibitors. All compounds demonstrated moderate to good calcium inhibitory effects at NMDA receptors in the range of 23% to 70% while a selected few displayed very little or no activity at the voltage gated calcium channels. In conclusion, 27 compounds with norbornane scaffolds were successfully synthesised and evaluated for cytotoxicity and neuroprotection. The abilities of the synthesised compounds to protect neurons from the neurotoxin MPP+ and reduce calcium flux into neuronal cells were successfully demonstrated. These characteristics are essential in neuroprotection as they may prove significant in halting or slowing down the disease progression. The compounds showing a good cytotoxicity profile, neuroprotective effects and ability to reduce calcium overload, could potentially act as neuroprotective agents with good safety profiles or contribute as lead structures to the development and design of structurally related molecules that could clinically benefit people with neurodegenerative disorders.
Kadernani, Yakub Esmail Y. E. "Novel adamantane derivatives as multifunctional neuroprotective agents." University of the Western Cape, 2013. http://hdl.handle.net/11394/4256.
Full textThe pathology of neurodegenerative disorders involves multiple steps, and it is probably for this reason that targeting one particular step in a multi-step process has only yielded limited results. Nitric oxide (NO) is synthesised from L-Arginine by an enzyme known as nitric oxide synthase (NOS). Three isoforms of NOS exist, including endothelial NOS (eNOS), neuronal NOS (nNOS), and inducible NOS (iNOS). In the central nervous system (CNS), nNOS is involved in the synthesis of NO, which is involved in various neurological functions. NO is a free radical and this probably explains why an excess amount of it has been implicated in the development of neurodegenerative disorders. In the CNS, the Nmethyl- D-aspartate (NMDA) receptor in its active state allows the influx of calcium ions which activate nNOS thus increasing the amount of NO and other detrimental reactive nitrogen species within neuronal cells. Calcium entry through voltage-gated calcium channels (VGCC) may also contribute to this. Although calcium ions are important for physiological functioning, an excess is responsible for excitotoxicity, which can ultimately lead to neurodegeneration. Our aim was to synthesise a series of adamantane-derived compounds that act at multiple target sites in the neurodegenerative pathway. By conjugating benzyl and phenylethyl moieties with different functional groups (-H, -NO2, -NH2, -NHC(NH)NH2, -OCH3) to the amantadine structure, we aimed to synthesise compounds that display calcium channel and NMDA receptor (NMDAR) channel inhibition, as well as selective inhibition of nNOS. A series of compounds (-H, -NO2, -NH2, -OCH3) were obtained in yields that varied between 16.5 % and 90.25 %. These novel compounds were tested for calcium influx through VGCC and NMDAR inhibition using synaptoneurosomes isolated from rat brain homogenate against the reference compounds MK-801, NGP1-01, amantadine, memantine and nimodipine. A lack of success with the synthesis of the guanidine compounds prevented the use of the oxyhemoglobin capture assay for the determination of nNOS inhibitory activity of these compounds. The novel synthesised compounds display inhibitory activity towards VGCC and the NMDAR in the micromolar range. Further tests are recommended on compounds SE-1, SE-4, SE-11 and SE-12 as they displayed good inhibitory activity against both NMDAR- as well as ii KCl-mediated calcium influx. These novel compounds may be better therapeutic options than amantadine and memantine as they inhibit both NMDAR and VGCC-mediated calcium influx, whereas amantadine and memantine only inhibit NMDA-mediated calcium influx. These novel adamantane derived compounds may possibly serve as novel leads or potential therapeutic agents for the treatment of neurodegenerative disorders.
Zindo, Frank T. "Polycyclic propargylamine derivatives as multifunctional neuroprotective agents." University of the Western Cape, 2018. http://hdl.handle.net/11394/6748.
Full textThe abnormal death of neurons in the central nervous system of individuals suffering from neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and amyotrophic lateral sclerosis, takes place by an intrinsic cell suicide programme known as apoptosis. This process is triggered by several stimuli, and consists of numerous pathways and cascades which lead to the death of neuronal cells. It is this multifactorial nature of neurodegenerative diseases that has over the years seen many researchers develop compounds that may serve as multi-target directed ligands (MTDLs) which could potentially confer neuroprotection by acting simultaneously on different receptors and target sites implicated in neurodegeneration. This study was aimed at developing MTDLs that may serve as neuroprotective agents by simultaneously (a) inhibiting N-methyl D-aspartate receptors (NMDAR) and blocking L-type voltage gated calcium channels (VGCC) thus regulating the Ca2+ influx mediated excitotoxic process; (b) inhibiting the monoamine oxidase enzymes A and -B (MAO-A/B) thus allowing increase in dopamine levels in the central nervous system and reducing the levels of the highly oxidative products produced by the activity of these enzymes; (c) possessing anti-apoptotic activity to halt the neuronal cell death process. In designing the compounds we focused on the structures of rasagiline and selegiline, two well-known MAO-B inhibitors and proposed neuroprotective agents, and of NGP1-01, a known VGCC blocker and NMDAR antagonist. The first series of compounds (reported in research article 1, Chapter 3), comprised polycyclic propargylamine and acetylene derivatives. Compounds 12, 15 and 16 from this series showed promising VGCC and NMDA receptor channel inhibitory activity ranging from 18 % to 59 % in micromolar concentrations, and compared favourably to the reference compounds. In the MAO-B assay, compound 10 exhibited weak MAO-B inhibition of 73.32 % at 300 μM. The rest of the series showed little to no activity on these target sites, despite showing significant anti-apoptotic activity. This suggested the compounds in this series to be exhibiting their neuroprotective action through some other mechanism(s) unexplored in this study.
Saathoff, John. "Curcumin/Melatonin Hybrids as Neuroprotective Agents for Alzheimer's disease." VCU Scholars Compass, 2016. http://scholarscompass.vcu.edu/etd/4586.
Full textHobbs, Catherine E., and n/a. "Perinatal hypoxia-ischaemia : neuroprotective strategies." University of Otago. Department of Anatomy & Structural Biology, 2005. http://adt.otago.ac.nz./public/adt-NZDU20070221.145910.
Full textSinger, Cherie A. "Neurotrophic and neuroprotective effects of estrogen /." Thesis, Connect to this title online; UW restricted, 1998. http://hdl.handle.net/1773/6301.
Full textMusakwa, Lovetone. "Chalcone and curcumin hybrids of indole propargylamines as multifunctional neuroprotective agents." University of the Western Cape, 2020. http://hdl.handle.net/11394/7959.
Full textNeurodegenerative disorders (NDs) are a range of chronic brain disorders that includes amongst others motor function loss. Parkinson’s disease (PD) is one of the common NDs that has an insidious onset and diagnosed when dopaminergic neurons in the substantia nigra are already lost. The loss creates a deficiency of the dopamine (neurotransmitter) thereby causing neurochemical imbalance resulting in the signs and symptoms of PD. NDs overlap at multiple levels so some of the symptoms overlap as well. NDs currently have no cure yet and current drug therapies only improve the quality of life of the patients by targeting the symptoms mainly. Treatment of PD currently involves different classes of drugs and depending on the stages of the disease, some drugs can be only used as an adjunct therapy. Anti-oxidants and monoamine oxidase inhibitors (MAO-I) are part of the treatment options.
Janis, Kelly Lynn. "Investigation of the efficacy of various neuroprotection agents for their potential use in the treatment of Parkinson's disease." Diss., Connect to online resource - MSU authorized users, 2008.
Find full textBooks on the topic "Neuroprotective agents"
International Conference on Neuroprotective Agents: Clinical and Experimental Aspects (8th 2006 Mackinac Island, Mich.). Neuroprotective agents. Edited by Slikker William, Andrews Russell J, Trembly Bruce, and New York Academy of Sciences. Malden, MA: Blackwell Pub. on behalf of the New York Academy of Sciences, 2007.
Find full textWilliam, Slikker, Trembly Bruce, and International Conference on Neuroprotective Agents: Clinical and Experimental Aspects (5th ; : 2000 : Lake Tahoe, Nev.), eds. Neuroprotective agents: Fifth international conference. New York, N.Y: New York Academy of Sciences, 2001.
Find full textWilliam, Slikker, and Trembly Bruce, eds. Neuroprotective agents: Third international conference. New York: New York Academy of Sciences, 1997.
Find full textInternational Conference on Neuroprotective Agents: Clinical and Experimental Aspects (9th 2008 Woods Hole, Mass.). Neuroprotective agents: Ninth international conference. Edited by Andrews Russell J. New York: New York Academy of Sciences, 2010.
Find full textLópez-Muñoz, Francisco, Venkataramanujam Srinivasan, Domenico de Berardis, Cecilio Álamo, and Takahiro A. Kato, eds. Melatonin, Neuroprotective Agents and Antidepressant Therapy. New Delhi: Springer India, 2016. http://dx.doi.org/10.1007/978-81-322-2803-5.
Full textBruce, Trembly, Slikker William, and International Conference on Neuroprotective Agents: Clinical and Experimental Aspects (2nd : 1994 : Lake George, N.Y.), eds. Neuroprotective agents: Clinical and experimental aspects. New York: New York Academy of Sciences, 1995.
Find full textV, Borlongan Cesario, Isacson Ole, and Sanberg Paul R, eds. Immunosuppressant analogs in neuroprotection. Totowa, N.J: Humana Press, 2003.
Find full textV, Borlongan Cesario, Isacson Ole, and Sanberg Paul R, eds. Immunosuppressant analogs in neuroprotection. Totowa, N.J: Humana Press, 2003.
Find full textV, Borlongan Cesario, Isacson Ole, and Sanberg Paul R, eds. Immunosuppressant analogs in neuroprotection. Totowa, N.J: Humana Press, 2003.
Find full textJain, K. K. The handbook of neuroprotection. New York: Humana Press, 2011.
Find full textBook chapters on the topic "Neuroprotective agents"
Jain, Kewal K. "Neuroprotective Agents." In The Handbook of Neuroprotection, 25–139. Totowa, NJ: Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-049-2_2.
Full textJain, Kewal K. "Neuroprotective Agents." In Springer Protocols Handbooks, 45–173. New York, NY: Springer New York, 2019. http://dx.doi.org/10.1007/978-1-4939-9465-6_2.
Full textCaltana, Laura R., and Alicia Brusco. "Cannabinoids: A Group of Promising Neuroprotective Agents." In Neuroprotective Natural Products, 321–39. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2017. http://dx.doi.org/10.1002/9783527803781.ch13.
Full textDev, Kapil, and Rakesh Maurya. "Marine-Derived Anti-Alzheimer's Agents of Promise." In Neuroprotective Natural Products, 153–84. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2017. http://dx.doi.org/10.1002/9783527803781.ch7.
Full textBurlakova, Elena B. "Antioxidant Drugs as Neuroprotective Agents." In Alzheimer Disease, 313–17. Boston, MA: Birkhäuser Boston, 1994. http://dx.doi.org/10.1007/978-1-4615-8149-9_52.
Full textVolsko, Christina, and Ranjan Dutta. "Neuroprotective Agents: An Overview on the General Modes of Action." In Neuroprotective Natural Products, 7–21. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2017. http://dx.doi.org/10.1002/9783527803781.ch2.
Full textPita, René, Eva Ramos, José Luis Marco-Contelles, and Alejandro Romero. "Melatonin as a Novel Therapeutic Agent Against Chemical Warfare Agents." In Melatonin, Neuroprotective Agents and Antidepressant Therapy, 177–91. New Delhi: Springer India, 2016. http://dx.doi.org/10.1007/978-81-322-2803-5_14.
Full textMahadik, Sahebarao P. "Gangliosides: New Generation of Neuroprotective Agents." In Emerging Strategies in Neuroprotection, 187–223. Boston, MA: Birkhäuser Boston, 1992. http://dx.doi.org/10.1007/978-1-4684-6796-3_10.
Full textFestoff, Barry W. "Clinical Potential of Agents That Affect Thrombin Signaling in Degenerative and Traumatic Neurologic Disorders." In Neuroprotective Signal Transduction, 221–41. Totowa, NJ: Humana Press, 1998. http://dx.doi.org/10.1007/978-1-59259-475-7_12.
Full textFernández-Moriano, Carlos, Elena González-Burgos, and Maria Pilar Gómez-Serranillos. "Lipid Peroxidation and Mitochondrial Dysfunction in Alzheimer's and Parkinson's Diseases: Role of Natural Products as Cytoprotective Agents." In Neuroprotective Natural Products, 107–51. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2017. http://dx.doi.org/10.1002/9783527803781.ch6.
Full textConference papers on the topic "Neuroprotective agents"
Merrill, Thomas L., Denise R. Merrill, and Jennifer E. Akers. "Localized Brain Tissue Cooling for Use During Intracranial Thrombectomy." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80083.
Full textAlza, Natalia, Valeria Cavallaro, Oriana Benzi Juncos, Ana Murray, and Gabriela Salvador. "<em>Cyclolepis genistoides</em> aqueous extract as source of neuroprotective agents." In 7th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2021. http://dx.doi.org/10.3390/ecmc2021-11536.
Full textTaraboletti, Alexandra, and Albert J. Fornace. "Abstract 3744: Repurposing the neuroprotective agent dimethyl fumarate against white matter damage and cognitive decline after radiotherapy." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-3744.
Full textTaraboletti, Alexandra, and Albert J. Fornace. "Abstract 3744: Repurposing the neuroprotective agent dimethyl fumarate against white matter damage and cognitive decline after radiotherapy." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-3744.
Full textTosatti, Jéssica, Adriana Fontes, Paulo Caramelli, and Karina Gomes. "EFFECTS OF RESVERATROL SUPPLEMENTATION ON THE COGNITIVE FUNCTION OF PATIENTS WITH ALZHEIMER’S DISEASE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS." In XIII Meeting of Researchers on Alzheimer's Disease and Related Disorders. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1980-5764.rpda026.
Full textAbd. Aziz, N. A. W., R. Agarwal, A. Abd Latiff, and N. M. Ismail. "RESVERATROL AS A POTENTIAL AGENT FOR NEUROPROTECTION AGAINST INTRACEREBRAL HEMORRHAGE: INSIGHT ON THE ROLE OF ADENOSINE A1 RECEPTORS." In MedChem-Russia 2021. 5-я Российская конференция по медицинской химии с международным участием «МедХим-Россия 2021». Издательство Волгоградского государственного медицинского университета, 2021. http://dx.doi.org/10.19163/medchemrussia2021-2021-88.
Full textSmith, Katisha D., and Liang Zhu. "Theoretical Evaluation of a Simple Cooling Pad Inducing Hypothermia in the Spinal Cord Following Traumatic Injury." In ASME 2009 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2009. http://dx.doi.org/10.1115/sbc2009-206190.
Full textReports on the topic "Neuroprotective agents"
Shih, Tsung-Ming A., Steven M. Duniho, and John H. McDonough. Control of Nerve Agent-Induced Seizures is Critical for Neuroprotection and Survival. Fort Belvoir, VA: Defense Technical Information Center, August 2002. http://dx.doi.org/10.21236/ada417799.
Full textLuan, Sisi, Wenke Cheng, Chenglong Wang, Hongjian Gong, and Jianbo Zhou. Impact of glucagon-like peptide 1 analogs on cognitive function among patients with type 2 diabetes mellitus. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0015.
Full text